This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Idenix Pharmaceuticals (IDIX)
Presentation at Morgan Stanley Global Healthcare Conference
September 10, 2012 1:15 p.m. ET
Ronald Renaud - President and CEO
Douglas Mayers - EVP and Chief Medical Officer
David Friedman - Morgan Stanley
PresentationDavid Friedman - Morgan Stanley
Thanks everyone for joining. Dave Friedman, biotech analyst here at Morgan Stanley. And for disclosure purposes, Morgan Stanley as well as personal holdings disclosures are available at morganstanley.com/researchdisclosures.
And I’m happy to have the team from Idenix up here. On the far side, Doug Mayers, chief medical officer; and on the nearside, Ron Renaud, president and CEO. And we’d look for this to be interactive and so any questions, anyone feel free to raise their hand. We’ll make sure we get to you. If I don’t see you, just yell or something and we’ll make sure.
My guess is most people know the company, but maybe for the one or two that don’t, if you can just give a couple minute overview of who you guys are and what you guys have going on?
First of all, thanks for having us. Idenix is a company focused on developing antivirals. Right now our singular focus is on direct-acting antivirals for the treatment of hepatitis C. We have taken a nucleoside across the finish line in hepatitis B, and that drug is now sold by Novartis. We did that in our previous collaboration with Novartis, and that drug is now on the market and sold in more than 60 countries worldwide.